Smart Inhalers Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The smart inhalers market size has grown rapidly in recent years. It will grow from $1.65 billion in 2024 to $1.81 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to increased medical adherence, increasing focus on patient-centric healthcare, growing demand for connected healthcare devices.

The smart inhalers market size is expected to see rapid growth in the next few years. It will grow to $2.66 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to rising prevalence of chronic respiratory diseases (CRDs), growing demand for home healthcare, increasing adoption of digital healthcare solutions. Major trends in the forecast period include technological advancements in smart inhalers, big data analytics, use of chip-on-sensors, advancements in sensor technology.

The increasing prevalence of chronic respiratory diseases (CRDs) is expected to fuel growth in the smart inhaler market. CRDs, including asthma and chronic obstructive pulmonary disease (COPD), are long-term conditions affecting lung function and quality of life. Smart inhalers aid in managing these diseases by tracking usage, reminding patients of missed doses, and supporting consistent medication adherence - key for controlling symptoms and reducing exacerbations. According to the 2022 National Health Survey by the Australian Bureau of Statistics, around 8.5 million Australians (34% of the population) are affected by CRDs, with approximately 2.8 million (11%) experiencing asthma and around 638,000 (2.5%) suffering from COPD. These conditions pose serious health and lifestyle challenges, making effective management essential. As the prevalence of CRDs continues to rise, so does the demand for smart inhalers, highlighting their importance in modern respiratory care.

Major companies operating in the smart inhaler market are developing advanced technologies, such as digital respiratory health solutions, to meet larger customer bases, increase sales, and increase revenue. A digital respiratory health solution refers to a technological intervention or platform designed to address and manage respiratory health conditions through digital means. For instance, in February 2022, Aptar Pharma, a US-based pharma service company, launched the HeroTracker Sense, an add-on connected device and a distinctive digital respiratory health solution designed to transform standard metered-dose inhalers (MDIs) into smart connected healthcare devices. Specifically designed for patients worldwide grappling with chronic respiratory diseases like asthma, COPD, cystic fibrosis, and conditions resulting from COVID-19, this next-generation MDI add-on device focuses on improving patients' lives. By attaching to the canister of an MDI, HeroTracker Sense offers advanced features, including sensors to track inhalation coordination, flow rate, and duration. It provides information through an accompanying app, offering date and time stamps for medication reminders and environmental monitoring alerts such as temperature and humidity. The device aims to enhance patient adherence to prescribed therapies by enabling informed and compliant medication intake.

In August 2022, AptarGroup Inc., a US-based pharmaceutical company, acquired worldwide rights to the proprietary Orbital dry powder inhaler (DPI) from Pharmaxis Inc. for an undisclosed amount. Orbital technology is designed to deliver high-payload dry powder to the lungs, allowing powder payloads of up to 400mg to be inhaled by patients in divided doses without the need to reload. The acquisition strengthens Aptar Pharma's position in respiratory drug delivery devices and associated services. Pharmaxis Inc. is an Australia-based pharmaceutical company that specializes in the development of dry powder inhalers (DPIs).

Major companies operating in the smart inhalers market are Novartis AG, AstraZeneca Plc, GlaxoSmithKline Plc., 3M Health Care Limited, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Berry Global Group Inc., Aptar Group Inc., Lupin Limited, Findair Sp.Z.o.o., OPKO Health Inc., Nemera France SAS, Vectura Group Limited, Propeller Health, Inspiro Medical Ltd., Biocorp Production, Cohero Health Inc., Pneuma Respiratory Inc., Amiko Digital Health Limited, Cognita Labs LLC, AireHealth Inc., Adherium Ltd., Zeolr Technologies Pvt Ltd., H&T Presspart Manufacturing Ltd.

North America was the largest region in the smart inhalers market in 2024. The regions covered in the smart inhalers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the smart inhalers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The smart inhalers market consists of sales of pressurized MDIs (metered-dose inhalers), breath-actuated MDIs (metered-dose inhalers), and related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Smart inhalers refer to medical devices that integrate connectivity with a mobile app, typically via Bluetooth. It is used to enhance the user experience and provide more personalized treatment decisions for individuals with chronic lung conditions such as asthma and chronic obstructive pulmonary disease (COPD).

The main types of smart inhalers are dry powdered inhalers (DPIs) and metered dose inhalers (MDIs). Dry powdered inhalers (DPIs) are a type of inhaler used to deliver medications, such as inhaled corticosteroids, into the lungs. They are used in the treatment of various indications, such as asthma, chronic obstructive pulmonary disease (COPD), and others, and are distributed through several distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies. These are used by various end-users, such as hospitals, homecare settings, and others.

The main types of smart inhalers are dry powdered inhalers (DPIs) and metered dose inhalers (MDIs). Dry powdered inhalers (DPIs) are a type of inhaler used to deliver medications, such as inhaled corticosteroids, into the lungs. They are used in the treatment of various indications, such as asthma, chronic obstructive pulmonary disease (COPD), and others, and are distributed through several distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies. These are used by various end-users, such as hospitals, homecare settings, and others.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.